Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3565
-$0.0556-13.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 3.45M | 3.14M | 2.98M | 6.00M | 2.80M |
| Total Receivables | -- | -- | 1.25M | 974.00K | 1.34M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 70.00K | 237.00K | 374.00K | 433.00K | 329.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 194.00K | 300.00K | 309.00K | 300.00K | 365.00K |
| Total Current Assets | 3.71M | 3.67M | 4.91M | 7.71M | 4.84M |
|
|
|||||
| Total Current Assets | 3.71M | 3.67M | 4.91M | 7.71M | 4.84M |
| Net Property, Plant & Equipment | 20.00K | 8.00K | 55.00K | 70.00K | 86.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | 412.00K | 413.00K | 413.00K | 1.24M |
| Total Assets | 3.73M | 4.09M | 5.38M | 8.19M | 6.17M |
|
|
|||||
| Total Accounts Payable | 114.00K | 4.60M | 4.13M | 4.74M | 5.20M |
| Total Accrued Expenses | 532.00K | 1.39M | 1.89M | 2.05M | 2.85M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 17.00K | 283.00K | 332.00K | 395.00K | 296.00K |
| Total Other Current Liabilities | 17.00K | 283.00K | 332.00K | 395.00K | 296.00K |
| Total Current Liabilities | 663.00K | 6.27M | 6.35M | 7.19M | 8.35M |
|
|
|||||
| Total Current Liabilities | 663.00K | 6.27M | 6.35M | 7.19M | 8.35M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 9.00K | -- | -- | 5.00K | 21.00K |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 672.00K | 6.27M | 6.35M | 7.19M | 8.37M |
|
|
|||||
| Common Stock & APIC | 443.52M | 438.21M | 436.51M | 436.40M | 429.92M |
| Retained Earnings | -440.46M | -439.49M | -436.44M | -434.49M | -431.23M |
| Treasury Stock & Other | 1.00K | -891.00K | -1.03M | -915.00K | -898.00K |
| Total Common Equity | 3.06M | -2.17M | -970.00K | 999.00K | -2.21M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 3.06M | -2.17M | -970.00K | 999.00K | -2.21M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 3.06M | -2.17M | -970.00K | 999.00K | -2.21M |
|
|
|||||